STOCK TITAN

TriSalus Life Sciences, Inc. - TLSI STOCK NEWS

Welcome to our dedicated page for TriSalus Life Sciences news (Ticker: TLSI), a resource for investors and traders seeking the latest updates and insights on TriSalus Life Sciences stock.

TriSalus Life Sciences, Inc. (symbol: TLSI) is engaged in the research, development, and sale of groundbreaking drug delivery technology and immuno-oncology therapeutics. The company's mission is to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers.

Core Business: TriSalus focuses on two main product lines: the Pressure Enabled Drug Delivery (PEDD) infusion systems and an investigational agent called SD-101 (nelitolimod). The PEDD infusion systems are already in use and are designed to enhance the delivery of therapeutic agents to tumors. The investigational agent SD-101 aims to stimulate the immune system to better combat hepatocellular cancer, pancreatic cancer, and other solid tumors located in the liver.

Recent Achievements: One of the company's major advancements is the development of TriNav, a new therapy delivery device that incorporates SmartValve technology to optimize the PEDD approach. This innovative device has the potential to significantly improve treatment efficacy and patient outcomes.

Current Projects: TriSalus is actively involved in clinical trials to evaluate the effectiveness of SD-101 in various types of liver and pancreatic cancers. These trials are crucial for securing future regulatory approvals and bringing new treatments to market.

Financial Condition: While detailed financial information is not provided, the company's ongoing research and development initiatives, coupled with its active market presence, indicate a robust commitment to transforming cancer treatment.

Partnerships: TriSalus collaborates with leading academic and medical institutions to advance its research and bring innovative therapies to patients. These partnerships are essential for the clinical validation and widespread adoption of its technologies.

Products:

  • PEDD Infusion Systems: These systems enhance drug delivery to tumors, increasing the efficacy of cancer treatments.
  • SD-101 (nelitolimod): An investigational agent designed to boost the immune system's response to liver and pancreatic cancers.
  • TriNav: The latest innovation in therapy delivery devices, featuring SmartValve technology to improve drug delivery efficiency.
Rhea-AI Summary

TriSalus Life Sciences (NASDAQ: TLSI) presented clinical data from its Phase 1b PERIO-02 trial at the ASCO 2024 Annual Meeting. The trial studies the hepatic arterial infusion (HAI) of nelitolimod using TriSalus's proprietary Pressure Enabled Drug Delivery (PEDD) technology in patients with hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The 4 mg dose showed promising results with all three patients achieving disease control, including one complete response, one partial response, and one stable disease. Follow-up is ongoing to determine the next steps. The PEDD method aims to improve drug delivery within tumor microenvironments, potentially enhancing treatment efficacy. Median progression-free survival for the 4 mg dose was over 120 days. The study also noted significant immune responses, including increased CD4 and CD8 T cells in liver tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.61%
Tags
-
Rhea-AI Summary

TriSalus Life Sciences (NASDAQ: TLSI), an oncology company, announced an exchange offer and consent solicitation for its various warrants. The initiative aims to simplify the capital structure and reduce the dilutive impact of these warrants. Holders of the Public Warrants, Private Placement Warrants, and Working Capital Warrants are offered to exchange their warrants for 0.30 shares of common stock per warrant. If adopted, the Warrant Amendment will require outstanding warrants to be exchanged at 0.27 shares per warrant. The offer involves up to 4,264,532 shares of common stock and seeks consents from warrant holders to amend the warrant agreements. The offer expires on June 25, 2024, and is managed by Oppenheimer & Co. Inc.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.75%
Tags
none
-
Rhea-AI Summary

TriSalus Life Sciences (Nasdaq: TLSI) reported its Q1 2024 financial results, highlighting a 116% year-over-year revenue increase to $6.5 million, driven by the TriNav® Infusion System. The gross margin improved to 85%, up from 78% in Q1 2023. Despite increased investments leading to an operating loss of $11.7 million and a net loss of $13.2 million, the company secured up to $50 million in debt financing with OrbiMed. Additionally, TriSalus appointed Liselotte Hyveled to its Board of Directors. The company forecasts full-year sales growth to exceed 50%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.49%
Tags
Rhea-AI Summary

TriSalus Life Sciences, a Nasdaq-listed oncology company, appointed Liselotte Hyveled to its Board of Directors. Hyveled, an industry veteran with over two decades of experience in pharmaceutical research and development, will contribute to TriSalus' vision of pioneering innovative treatments for liver and pancreatic cancers. Her strategic insights and patient-centric approach will be important in shaping the company's growth trajectory and advancing its technology and therapeutic pipelines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
management
-
Rhea-AI Summary

TriSalus Life Sciences, a Nasdaq-listed oncology company, will host a conference call on May 15, 2024, at 9:00 a.m. ET to discuss first-quarter financial results and provide a business update. The call will cover the period ending March 31, 2024, and will be webcast live on their investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences earnings
-
Rhea-AI Summary

TriSalus Life Sciences has secured up to $50 million in debt financing with OrbiMed to support the growth of its TriNav® Infusion System. $25 million was funded initially, with an option for an additional $25 million based on revenue thresholds. The financing is expected to fuel strategic expansion, extending the cash runway through 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
TriSalus Life Sciences Inc. (TLSI) reported strong financial results for Q4 2023 with revenues of $5.7 million, up 77% YoY, and full-year revenues of $18.5 million, up 49% YoY. The company achieved a gross margin of 90% in Q4 2023 and 86% for the full year. TriSalus received CMS reimbursement for its TriNav Infusion System and published real-world data showing improved therapeutic delivery to liver tumors. They obtained 510k clearance for TriNav Large and TriGuide systems, completed phase 1 trials for liver indications, and initiated a phase 1 trial for a novel pancreatic infusion technology. The company also reported operating losses of $14.1 million in Q4 and $54.2 million for the full year, with net losses of $35.5 million in Q4 and $59.0 million for the full year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
-
Rhea-AI Summary
TriSalus Life Sciences Inc. (TLSI) presents new safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer and a retrospective clinical study supporting the TriNav Infusion System. The technology integrates novel delivery methods with immunotherapy for liver and pancreatic tumors, featured at the Society of Interventional Radiology Annual Scientific Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
TriSalus Life Sciences Inc. (TLSI) will present data at the 2024 Society of Interventional Radiology Annual Scientific Meeting on their Pressure-Enabled Drug Delivery technology for liver and pancreatic tumors. The company aims to address challenges in delivering therapeutics to pancreas tumors by modulating pressure and flow. TLSI is committed to transforming therapeutic delivery into challenging tumors and improving outcomes in solid tumor indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.95%
Tags
none
Rhea-AI Summary
TriSalus Life Sciences Inc. (TLSI) reports strong Q4 sales of approximately $5.7 million, representing 77% growth compared to 2022. Gross margins for Q4 and full year 2023 stand at around 90% and 86% respectively. Full year 2024 sales growth is expected to exceed 50%. The company anticipates having sufficient liquidity to fund operations into the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags

FAQ

What is the current stock price of TriSalus Life Sciences (TLSI)?

The current stock price of TriSalus Life Sciences (TLSI) is $4.07 as of November 20, 2024.

What is the market cap of TriSalus Life Sciences (TLSI)?

The market cap of TriSalus Life Sciences (TLSI) is approximately 125.6M.

What does TriSalus Life Sciences, Inc. do?

TriSalus Life Sciences focuses on developing drug delivery technology and immuno-oncology therapeutics to improve outcomes for liver and pancreatic cancer patients.

What are the main products of TriSalus Life Sciences?

The main products include the Pressure Enabled Drug Delivery (PEDD) infusion systems and an investigational agent called SD-101 (nelitolimod).

What is TriNav?

TriNav is a new therapy delivery device with SmartValve technology, designed to optimize the Pressure Enabled Drug Delivery (PEDD) approach.

What types of cancer does TriSalus target?

TriSalus targets difficult-to-treat liver and pancreatic cancers.

What is the purpose of SD-101 (nelitolimod)?

SD-101 is an investigational agent aimed at boosting the immune system's response to combat hepatocellular cancer, pancreatic cancer, and other liver solid tumors.

Is TriSalus involved in any clinical trials?

Yes, TriSalus is actively conducting clinical trials to evaluate the effectiveness of SD-101 in treating liver and pancreatic cancers.

Who are TriSalus' partners?

TriSalus collaborates with leading academic and medical institutions to advance its research and develop new therapies.

How can I stay updated on TriSalus' latest news?

You can stay updated by following their latest news on financial websites like StockTitan, or the company's official website and press releases.

What is the significance of the PEDD infusion systems?

The PEDD infusion systems enhance the delivery of therapeutic agents to tumors, potentially improving the efficacy of cancer treatments.

Where can I find more information about TriSalus stock?

For the latest updates and relevant information about TriSalus' stock performance, visit financial websites like StockTitan or consult stock market resources.

TriSalus Life Sciences, Inc.

Nasdaq:TLSI

TLSI Rankings

TLSI Stock Data

125.62M
17.79M
43.32%
17.27%
0.19%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
WESTMINSTER